Tags

Type your tag names separated by a space and hit enter

Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes.
Nutr J. 2013 Jul 15; 12:98.NJ

Abstract

BACKGROUND

The extent to which long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) from fish oil such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert their anti-inflammatory effects by down-regulating intestinal inflammation in humans is unknown. We investigated the impact of LCn-3PUFA supplementation on inflammatory gene expression in the duodenum of obese patients with type 2 diabetes.

FINDINGS

This placebo-controlled randomized crossover study included 12 men with type 2 diabetes. After a 4-week run-in period, patients received in a random sequence 5 g/d of fish oil (providing 3 g of EPA + DHA) and a placebo (corn and soybean oil) for 8 weeks each. The two treatment phases were separated by a 12-week washout period. Gene expression was assessed by real-time polymerase chain reaction in duodenal biopsy samples obtained in the fasted state at the end of each treatment phase. Intestinal mRNA expression levels of interleukin (IL)-6 and tumor-necrosis factor (TNF)-α were hardly detectable after either treatment (<100 copies/105 copies of the reference gene ATP5o). Intestinal mRNA expression of IL-18 and of the transcription factor signal transducer and activator of transcription 3 (STAT3) was higher (>5000 copies/105 copies ATP5o) but still relatively low. EPA + DHA supplementation had no impact on any of these levels (all P ≥ 0.73).

CONCLUSIONS

These data suggest that duodenal cells gene expression of pro-inflammatory cytokines is low in patients with type 2 diabetes and not affected by EPA + DHA supplementation. Further studies are warranted to determine if inflammatory gene expression in other tissues surrounding the intestine is modulated by EPA + DHA supplementation.

TRIAL REGISTRATION

ClinicalTrials.gov ID: NCT01449773.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23855973

Citation

Labonté, Marie-Ève, et al. "Eicosapentaenoic and Docosahexaenoic Acid Supplementation and Inflammatory Gene Expression in the Duodenum of Obese Patients With Type 2 Diabetes." Nutrition Journal, vol. 12, 2013, p. 98.
Labonté MÈ, Couture P, Tremblay AJ, et al. Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes. Nutr J. 2013;12:98.
Labonté, M. È., Couture, P., Tremblay, A. J., Hogue, J. C., Lemelin, V., & Lamarche, B. (2013). Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes. Nutrition Journal, 12, 98. https://doi.org/10.1186/1475-2891-12-98
Labonté MÈ, et al. Eicosapentaenoic and Docosahexaenoic Acid Supplementation and Inflammatory Gene Expression in the Duodenum of Obese Patients With Type 2 Diabetes. Nutr J. 2013 Jul 15;12:98. PubMed PMID: 23855973.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes. AU - Labonté,Marie-Ève, AU - Couture,Patrick, AU - Tremblay,André J, AU - Hogue,Jean-Charles, AU - Lemelin,Valéry, AU - Lamarche,Benoît, Y1 - 2013/07/15/ PY - 2013/02/20/received PY - 2013/07/09/accepted PY - 2013/7/17/entrez PY - 2013/7/17/pubmed PY - 2015/3/31/medline SP - 98 EP - 98 JF - Nutrition journal JO - Nutr J VL - 12 N2 - BACKGROUND: The extent to which long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) from fish oil such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert their anti-inflammatory effects by down-regulating intestinal inflammation in humans is unknown. We investigated the impact of LCn-3PUFA supplementation on inflammatory gene expression in the duodenum of obese patients with type 2 diabetes. FINDINGS: This placebo-controlled randomized crossover study included 12 men with type 2 diabetes. After a 4-week run-in period, patients received in a random sequence 5 g/d of fish oil (providing 3 g of EPA + DHA) and a placebo (corn and soybean oil) for 8 weeks each. The two treatment phases were separated by a 12-week washout period. Gene expression was assessed by real-time polymerase chain reaction in duodenal biopsy samples obtained in the fasted state at the end of each treatment phase. Intestinal mRNA expression levels of interleukin (IL)-6 and tumor-necrosis factor (TNF)-α were hardly detectable after either treatment (<100 copies/105 copies of the reference gene ATP5o). Intestinal mRNA expression of IL-18 and of the transcription factor signal transducer and activator of transcription 3 (STAT3) was higher (>5000 copies/105 copies ATP5o) but still relatively low. EPA + DHA supplementation had no impact on any of these levels (all P ≥ 0.73). CONCLUSIONS: These data suggest that duodenal cells gene expression of pro-inflammatory cytokines is low in patients with type 2 diabetes and not affected by EPA + DHA supplementation. Further studies are warranted to determine if inflammatory gene expression in other tissues surrounding the intestine is modulated by EPA + DHA supplementation. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT01449773. SN - 1475-2891 UR - https://www.unboundmedicine.com/medline/citation/23855973/Eicosapentaenoic_and_docosahexaenoic_acid_supplementation_and_inflammatory_gene_expression_in_the_duodenum_of_obese_patients_with_type_2_diabetes_ L2 - https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-12-98 DB - PRIME DP - Unbound Medicine ER -